Thursday, 4 August 2022

A Renewable Relationship between Epilepsy and Quinazolinones| Chapter 7 | Challenges and Advances in Pharmaceutical Research Vol. 5

 

 There must be a global response to the public health problem of epilepsy. No matter where it occurs in the world, epilepsy affects people of all ages, genders, races, and social backgrounds. The cortical area of the brain's excessive cortical neuron firing frequently results in the epileptic condition. Understanding the different types of epileptic episodes is the first step in determining an accurate epilepsy diagnosis, course of therapy, and prognosis. Particular seizure types or diseases usually respond better to particular medications or surgical methods. The largest difficulty in treating epilepsy is multidrug resistance syndrome and refractory epilepsy because they prevent Anti-Epileptic Drugs (AEDs) from reaching their intended target in the central nervous system. Additionally, the medications that are already on the market have harmful side effects such sleepiness, hepatotoxicity, anaemia, and teratogenicity. It is crucial to find new medications that are both safe and efficient. Analogues of quinazolinones are molecules that can bind to several sites with high affinity and speed up the development of valuable compounds with therapeutic activity. Novel quinazolinone derivatives have been developed by several scientists from across the world and have been virtually screened and evaluated for their potential to cure various types of seizures. They will be extremely important in the future management of epilepsy.

Author(s) Details:

H. S. Al-Salem,
Department of Pharmaceutical Chemistry, King Saud University, Saudi Arabia.

T. O. Mirgany,
Department of Pharmaceutical Chemistry, King Saud University, Saudi Arabia.

Please see the link here: https://stm.bookpi.org/CAPR-V5/article/view/7775   

No comments:

Post a Comment